gene in patients relapsing right after treatment method With all the BCL2 antagonist venetoclax. 66 Resistance to these brokers has become connected with these mutations in around 70% of conditions, Despite the fact that they are generally subclonal as well as their distinct purpose producing resistance really should be tested.??? "????????????????